

CLINICAL PRACTICE

Portuguese recommendations for the use of biological and targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis – 2020 update

Fernandes BM¹, Guimarães F², Almeida DE³, Neto A⁴, Tavares-Costa J², Ribeiro AR³, Quintal A⁴, Pereira JP⁵, Silva L⁶, Nóvoa TS⁷, Faustino A⁸, Vaz C⁹, Khmelinskii N⁵, Samões B¹⁰, Dourado E⁵, Silva JL³, Barcelos A¹¹, Mariz E¹, Guerra M¹², Santos MJ¹³, Silvério-António M⁵, Teixeira RL⁵, Romão VC⁵, Santos H⁸, Santos-Faria D², Azevedo S², Rodrigues A¹⁴, Dias JM¹⁵, Lopes C¹⁶, Pinto P¹⁰, Couto M¹⁷, Miranda LC⁸, Bernardo A¹², Cruz M¹⁸, Teixeira F², Mourão AF¹⁶, Neto A⁸, Teixeira V¹⁹, Cordeiro A¹³, Barreira S⁵, Inês LS²⁰, Capela S⁵, Sepriano A¹⁶, Canhão H²¹, Fonseca JE⁵, Duarte C^{20†}, Bernardes M[†]

ABSTRACT

Objective: To update the recommendations for the treatment of rheumatoid arthritis (RA) with biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs), endorsed by the Portuguese Society of Rheumatology (SPR).

Methods: These treatment recommendations were formulated by Portuguese rheumatologists taking into account previous recommendations, new literature evidence and consensus opinion. At a national meeting, in a virtual format, three of the ten previous recommendations were re-addressed and discussed after a more focused literature review. A first draft of the updated recommendations was elaborated by a team of SPR rheumatologists from the SPR rheumatoid arthritis study group, GEAR. The resulting document circulated among all SPR rheumatologists for discussion and input. The level of agreement with each of all the recommendations was anonymously voted online by all SPR rheumatologists.

Results: These recommendations cover general aspects such as shared decision, treatment objectives, systematic assessment of disease activity and burden and its registry in Reuma.pt. Consensus was also achieved regarding specific aspects such as initiation of bDMARDs and tsDMARDs, assessment of treatment response, switching and definition of persistent remission.

Conclusion: These recommendations may be used for guidance of treatment with bDMARDs and tsDMARDs in patients with RA. As more evidence becomes available and more therapies are licensed, these recommendations will be updated.

Keywords: Targeted synthetic disease-modifying antirheumatic drugs; Guidelines; Rheumatoid arthritis; Biologics.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, with an estimated prevalence of 0.7% in the adult Portuguese population¹. The management

of RA rests primarily on the use of disease-modifying anti-rheumatic drugs (DMARDs). These drugs reduce or reverse signs and symptoms, disability, impairment of quality of life, inability to work, and progression of

¹Reumatologia, Centro Hospitalar Universitário de São João, Porto;

²Reumatologia, Unidade Local de Saúde do Alto Minho, Ponte de Lima; ³Reumatologia, Hospital de Braga, Braga; ⁴Reumatologia, Centro Hospitalar do Funchal, Hospital Dr. Nélio Mendonça, Funchal; ⁵Reumatologia, Centro Hospitalar de Lisboa Norte, Hospital de Santa Maria, Lisboa; ⁶Reumatologia, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real; ⁷Reumatologia, Hospital do Divino Espírito Santo, Ponta Delgada; ⁸Reumatologia, Instituto Português de Reumatologia, Lisboa; ⁹Reumatologia, Unidade Local de Saúde da Guarda, Guarda; ¹⁰Reumatologia, Centro Hospitalar de Vila Nova de Gaia/ Espinho, Vila Nova de Gaia; ¹¹Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro; ¹²Reumatologia, Centro Hospitalar da Cova da Beira, Covilhã; ¹³Reumatologia, Hospital Garcia de Orta, Almada; ¹⁴Reumatologia, Hospital de Santo Espírito da Ilha Terceira, Angra do Heroísmo; ¹⁵Reumatologia, Centro Hospitalar do Médio Tejo, Tomar

¹⁶Reumatologia, Centro Hospitalar de Lisboa Ocidental, Hospital de Egas Moniz, Lisboa; ¹⁷Reumatologia, Centro Hospitalar Tondela/ Viseu, Viseu; ¹⁸Reumatologia, Consultórios Médicos de Caldas da Rainha, Caldas da Rainha; ¹⁹Reumatologia, Centro Hospitalar Universitário do Algarve, Hospital de Faro, Faro; ²⁰Reumatologia, Centro Hospitalar Universitário de Coimbra, Coimbra; ²¹Reumatologia, Centro Hospitalar de Lisboa Central, Hospital de Santo António dos Capuchos, Lisboa

*These authors contributed equally to this work

†These authors contributed equally to the supervision of this work

Submitted: 25/07/2021

Accepted: 22/09/2021

Correspondence to: Miguel Bernardes
E-mail: mbernardes09@gmail.com

joint damage and thus interfere with the entire disease process. DMARDs include biological agents (bDMARDs), conventional synthetic (csDMARDs) and targeted synthetic (tsDMARDs) chemical compounds². The appropriate use of anti-rheumatic drugs is critical. It should be initiated as soon as the diagnosis is established, since its delay is associated with progressive joint damage accrual and lower likelihood of achieving a drug-free remission³. The treatment objective should be to reach remission at the earliest possible time point, based on a Treat-to-Target (T2T) strategy. T2T epitomizes the consensual concept that disease treatment should aim to achieve a target level of disease activity as early as possible and consistently maintain it^{4,5}. Clinical disease remission, or at least low disease activity, has become a possible and virtually mandatory target of treatment in recent treatment recommendations^{2,6}.

Biological therapies with different mechanisms of action are currently approved for RA. In Portugal, five original tumour necrosis factor inhibitors (TNFi) (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol), one interleukin (IL)-6 receptor (IL-6R) blocking monoclonal antibody (tocilizumab), a T cell stimulation inhibitor (abatacept) and one B cell depleting agent (rituximab) are available. Currently bi-similar (bs) of infliximab, adalimumab, etanercept and rituximab (bs-infliximab, bs-adalimumab, bs-etanercept and bs-rituximab, respectively) are also available. Other bs will soon enter the Portuguese market.

More recently, tsDMARDs were approved for RA treatment. They have overlapping mechanisms of action, despite having different selectivity and inhibition profiles⁷⁻⁹. Three Janus kinase inhibitors (JAKi) (baricitinib, tofacitinib and upadacitinib) are currently available in Portugal. Filgotinib, a JAKi already approved by the European Medicines Agency (EMA) for RA treatment, will soon enter the Portuguese market¹⁰.

In 2003, the first version of the Portuguese Recommendations for the treatment of RA with biological therapy was developed by the Rheumatoid Arthritis Study Group (GEAR – Grupo de Estudos de Artrite Reumatóide) of the Portuguese Society of Rheumatology (SPR – Sociedade Portuguesa de Reumatologia) and published in *Acta Reumatológica Portuguesa*¹¹. These guidelines have been regularly updated as new evidence is published and the experience of their use increases, with the latest recommendations published in 2016¹²⁻¹⁶. These recommendations are based on the standardized use of validated assessment tools of RA activity and impact: the disease activity score 28-joint count (DAS 28)¹⁷, the Health Assessment Questionnaire (HAQ)¹⁸ and the radiological assessment of Sharp score modified by van der Heijde (SvdH)¹⁹. A structured national registry of rheumatic patients (Reuma.pt), incorporat-

ing disease assessment tools for RA, has been created by the SPR and is available online²⁰.

This article presents the 2020 update of the Portuguese recommendations for the use of bDMARDs and tsDMARDs in RA. The review process focused primarily on the content of recommendations 6, 8 and 10. For its part, recommendations 1, 2, 3, 4, 5, 7 and 9 remained mostly unchanged compared to 2016. Although these recommendations contain some original concepts, their general structure follows the pattern of other international recommendations². These recommendations were formulated by a team of SPR rheumatologists from the SPR rheumatoid arthritis study group, GEAR, based on literature evidence and consensus opinion. A national meeting was held, in virtual format, for presentation of new evidence, discussion and rephrasing of recommendations 6, 8 and 10, with the presence of forty-two SPR rheumatologists. A draft of the recommendations and supporting evidence was first circulated among all SPR rheumatologists for discussion and input. Finally, the level of agreement with each of all the recommendations was anonymously voted online by all SPR rheumatologists. Agreement was measured on a 10-point numerical rating scale (1=no agreement, 10=full agreement). These recommendations may be used for guidance in deciding which patients with RA should be treated with bDMARDs and tsDMARDs, how they should be monitored and which of them should be maintained on these therapies. The use of those therapies in RA is a rapidly evolving field and as more evidence becomes available and more therapies are licensed, these recommendations will be updated.

RECOMMENDATION 1

Rheumatologists are the specialists who should primarily care for RA patients. Treatment of RA patients with bDMARDs and tsDMARDs must be based on a shared decision between patient and rheumatologist.

The rheumatologist is the specialist who should treat and monitor patients with RA. There is current evidence that patients with RA followed up by rheumatologists, in comparison with other physicians, are diagnosed earlier, receive DMARD treatment earlier and have better outcomes in all major manifestations of RA²¹⁻²⁷. Nevertheless, since patients with RA have a high risk not only for disabilities related to their joint disease but also for comorbidities, such as infections, cardiovascular disease or malignancies, a multidisciplinary approach may be required in some cases.

Sharing medical decisions is the foundation of the partnership between physicians and patients. Shared decision is established between an individual Rheuma-

tologist and his Patient, as individuals, and should be considered a fundamental part of patient-doctor relationship and trust. It involves agreeing on the problem at hand, laying out the available options with their benefits and risks, eliciting the patient's views and preferences on these options, and agreeing on a course of action. Shared decision making not only increases patient and physician satisfaction with healthcare, but also may improve health outcomes^{28, 29}. This recommendation focuses on the need for patient information regarding the risks and benefits of the treatment. Due to the complexity, high cost, and potential toxicity of therapies for RA, patient information is central to safety and quality of care.

RECOMMENDATION 2
Monitoring RA patients under treatment with bDMARDs and tsDMARDs is mandatory. These patients should be evaluated at closely spaced intervals, no longer than 3-4 months, to assess disease activity and safety issues. Function, quality of life and damage should also be evaluated during follow-up.

Follow-up should be provided at regular intervals, no longer than 3-4 months, for monitoring the efficacy of bDMARDs and tsDMARDs and identifying potential side effects. Tender and swollen joint counts, inflammatory markers [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)], patient global assessment of disease activity (PGA) and physician global assessment (PhGA) should be collected at each evaluation. Patients should be evaluated using composite activity indexes (Table I). The most commonly used index is the DAS28 ESR, which has validated cut-offs for different activity levels^{14, 30}. Other composite measures using joint counts, with validated cut-offs for disease activity, can be used, such as the Simplified Disease Activity Index (SDAI)³¹ or the Clinical Disease Activity Index (CDAI)³². The DAS28 CRP has no validated cut-offs for remission or low disease activity. All these variables and indexes are available in Reuma.pt. The global impact of the disease should also be evaluated. Assessment of functional impact using the HAQ, a validated tool available in Portuguese³³, should be performed when starting bDMARDs/ tsDMARDs and every six months thereafter. Physical Function not only provides information about the impact of RA but also predicts future outcomes. Quality of life (QoL) should also be regularly assessed. Generic tools, as the Medical Outcome Study Short Form 36-item (MOS-SF36)^{34, 35} and the EuroQol five dimensions questionnaire (EQ5D)³⁶⁻³⁸ are validated in Portuguese and available in Reuma.pt. Structural disease progression should be evaluated, on radiographs

Table I. Instruments to measure rheumatoid arthritis disease activity and to define remission (Adapted from ⁶)

Instrument	Thresholds of disease activity	
DAS28-ESR ²⁵	Remission	<2.6
	Low Activity	≥2.6 to <3.2
	Moderate Activity	≥3.2 to ≤5.1
	High Activity	>5.1
SDAI ²⁶	Remission	≤3.3
	Low Activity	>3.3 to ≤11
	Moderate Activity	>11 to ≤26
	High Activity	>26
CDAI ²⁷	Remission	≤2.8
	Low Activity	>2.8 to ≤10
	Moderate Activity	>10 to ≤22
	High Activity	>22

DAS 28-ESR: 28-joint Disease Activity Score Erythrocyte Sedimentation Rate; SDAI: Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index.

of hands and feet, when starting bDMARDs/ tsDMARDs and repeated thereafter to support future treatment decision.

RECOMMENDATION 3
All RA patients receiving bDMARDs and tsDMARDs should be prospectively registered in the Reuma.pt.

Registries of patients with rheumatic diseases, especially under treatment with bDMARDs and tsDMARDs, allow monitoring of the treatment's efficacy and safety. These registries have contributed to the increasing knowledge on the performance of these drugs in the real world. All instruments required to monitoring RA patients are available in Reuma.pt²⁰.

RECOMMENDATION 4
The treatment target is remission or, at least, low disease activity.

Besides clinical benefit, remission status has a significant impact on progression of joint damage and deformities, physical function, QoL, comorbidities and mortality^{39, 40}. Remission is considered as the absence of symptoms and signs of inflammation. The several available disease activity indexes define "remission status" differently (Table I)³⁰⁻³². Observational studies have shown that remission definitions are only partially overlapping across the several indexes, being the DAS28-ESR the least stringent criteria⁴¹⁻⁴³. In 2011, collaborative research of the American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) defined remission as having all the following measure-

ments below 1: tender joint count, swollen joint count, CRP and patient global assessment of disease activity⁴⁴. These new criteria are associated with lower risk of radiographic progression and better outcomes^{45, 46}. The proportion of patients reaching remission in clinical trials and clinical practice is sufficiently large to warrant its preferential use in clinical practice². However, some studies have shown that many patients without clinical and laboratory findings of inflammation cannot be classified as being in remission due to the inclusion of PGA, making the ACR/EULAR remission difficult to apply in daily clinical practice, particularly in some clinical settings (eg. chronic pain syndrome, depression)⁴⁷. In this context, PGA score might be in a large proportion due to other factors not related to inflammatory arthritis. In these difficult cases, more relevance can be given to the objective measures, like the inflammatory markers and swollen joints, since only those have been shown consistently to be associated with radiographic progression^{48, 49}. In some cases, like patients with long-standing or destructive joint disease, in whom remission status is not achievable, low disease activity is acceptable².

RA patients report significant levels of disease impact, which are improved, but not fully abrogated by immunosuppressive therapy, even when remission is achieved. Therefore, there is a need for adjuvant interventions aimed at other uncontrolled domains of disease impact. This issue is detailed in the Portuguese multidisciplinary recommendations for non-pharmacological and non-surgical interventions in RA patients⁵⁰.

RECOMMENDATION 5
RA patients with inadequate response to methotrexate (MTX) at an optimal dose and for an adequate period of time, or to at least one other csDMARD or in case of contraindication or intolerance to MTX, should be considered for bDMARDs or tsDMARDs therapy.

MTX is the anchor treatment for RA patients, used in monotherapy or combined therapy, and should be part of RA's first-line treatment². In case of contraindication or intolerance to MTX, leflunomide or sulfasalazine should be started. The optimal dosage of MTX is 25 mg/week for at least eight weeks⁵¹. The optimal dosage of leflunomide is 20 mg/day and of sulfasalazine is 3 g/day and may require a longer period to achieve optimal benefit^{2, 52}. All patients with no clinical improvement after three months and all patients who fail to achieve at least low disease activity (DAS <3.2) at six months after starting csDMARD therapy should be considered as inadequate responders, and treatment should therefore be escalated to a bDMARD or a tsDMARD.

Short-term glucocorticoids should be considered

as bridging therapy when initiating or changing csDMARD, in different dose regimens and routes of administration, but should be tapered as rapidly as clinically feasible².

RECOMMENDATION 6
If it is not possible to achieve the treatment target with an optimal csDMARD strategy or if there is contraindication/intolerance to it, a bDMARD or a tsDMARD should be considered, preferably combined with a csDMARD. In patients who cannot use csDMARDs, IL-6 inhibitors or tsDMARDs should be considered.

Therapy with bDMARDs should be initiated with one of the following drugs authorized for first-line use: TNFi (infliximab, etanercept, adalimumab, golimumab, certolizumab pegol or approved respective bs) or tocilizumab. All the drugs mentioned above plus abatacept have been proven to effectively control disease activity, improve different patient-reported outcomes (PROs) and slow structural disease progression⁵³⁻⁷⁹. Unfortunately, in Portugal, abatacept is only reimbursed as second-line biological treatment, after failing to respond to at least one TNFi.

Indirect comparison between the different bDMARDs⁸⁰⁻⁸² and data from few head-to-head studies^{74, 75, 83} did not show statistically significant differences in efficacy and safety between them. Since no factors are available for guiding drug selection, no preference for one over another agent is recommended. However, recent data from the nationwide Swedish register suggests that, as a first-line biologic treatment, non-TNFi (abatacept, rituximab and tocilizumab) showed better retention rate and efficacy (1-year EULAR Good Response/HAQ improvement) compared with TNFi, being tocilizumab the most efficacious and rituximab the drug with the longest retention⁸⁴. These data are in line with findings from Reuma.pt, wherein treatment with tocilizumab in bDMARD-naïve patients was associated with better short-term effectiveness⁸⁵. These results defy TNFi preference in daily practice⁸⁶, and require further validation with additional evidence. Moreover, a systematic review of the literature with the objective to provide an evidence-based decisional statement for the first-line biologic therapy in RA showed that the following preferences should be specially considered: abatacept in patients with high risk of infection; abatacept or tocilizumab in presence of latent tuberculosis infection and in patients with high rheumatoid factor and anti-citrullinated protein antibodies titers; etanercept in case of high cardiovascular risk⁸⁷. Additionally, in a pooled analysis of sixteen observational RA reg-

istries, seropositivity for rheumatoid factor and/or anti-citrullinated protein antibodies was associated with increased effectiveness of rituximab and abatacept, but not TNFi⁸⁸.

Rituximab combined with MTX has proven efficacy in treating RA after TNFi failure⁸⁹⁻⁹⁹ and is currently approved as second-line therapy. Pivotal trials for Rituximab approval were done in TNFi-naïve patients and showed its efficacy also in this context¹⁰⁰. Moreover, rituximab has also been studied in patients with active RA that have not been previously exposed to MTX. In the IMAGE trial, rituximab plus MTX was effective in reducing signs and symptoms of the disease as well as preventing radiographic damage in MTX-naïve patients with early RA¹⁰¹. Another study also showed improvement of physical function and quality of life in a similar population¹⁰². Rituximab is not licensed for use as a first-line biological agent therapy. However, it can be used in first-line under specific conditions (see recommendation 7).

Therapy with tsDMARDs should be initiated with one of the following JAKis: tofacitinib (mainly JAK 1/3 inhibitor), baricitinib (JAK 1/2 inhibitor) or upadacitinib (selective JAK 1 inhibitor); all are approved by EMA and available in Portugal, in monotherapy or association with csDMARDs, for the treatment of moderate to severe RA in patients with inadequate response or intolerance to MTX.

In recent years, more data has emerged on the efficacy of JAKis: in the ORAL strategy trial, a double-blind, head-to-head, randomized, controlled trial, tofacitinib in combination with MTX demonstrated to be non-inferior to adalimumab in combination with MTX (difference 2% [98.34% CI -6 to 11])¹⁰³; moreover, a double-blind, phase 3, placebo- and active-controlled trial showed that baricitinib in combination with MTX had better efficacy than adalimumab in combination with MTX¹⁰⁴. Additionally, in a double-blind, phase 3, randomized, controlled trial, upadacitinib proved to be superior to placebo and adalimumab for improving signs, symptoms and physical function in RA patients who were receiving background MTX¹⁰⁵. These latest results were confirmed at 48 weeks in the extension study¹⁰⁶. Hence, in patients with RA irresponsive to csDMARDs, JAKi in combination with MTX demonstrated superiority or non-inferiority in comparison with adalimumab plus MTX.

In the absence of a head-to-head comparison of tofacitinib, baricitinib and upadacitinib, no preference of one over another can be advocated.

The most commonly reported side effects with JAKis are nausea, headache, iatrogenic dyslipidaemia, increased levels of transaminases and creatinine, changes in leukocyte and erythrocyte count, herpes zoster

reactivations and respiratory/urinary infections¹⁰⁷⁻¹⁰⁹. Current evidence does not indicate an increased risk of malignancy with JAKis¹¹⁰⁻¹¹³. Available data suggests that there is no difference in the infection risk between JAKis and bDMARDs, except for the increased risk of herpes zoster infection with JAKis, which appear to be a class effect and more frequent in Asian populations^{110, 111, 114, 115}. A recent systematic review and meta-analysis of randomized controlled trials assessed the cardiovascular risk of JAKis in RA, revealing no significant change in cardiovascular risk in a short-term perspective. However, more data are needed due to the reported increased risk of thromboembolism detected for both tofacitinib and baricitinib at higher doses¹¹⁶. Recently, data from the ORAL Surveillance, a post-marketing study including 4362 RA patients designed to compare the safety of tofacitinib versus TNFi with respect to major cardiovascular adverse events and malignancies (excluding non-melanoma skin cancers) showed that both primary endpoints (non-inferiority of tofacitinib compared to TNFi regarding major adverse cardiovascular events and malignancies) were not met. Moreover, there was no difference in those endpoints between the two doses of tofacitinib (5 mg twice daily and 10 mg twice daily)¹¹⁷.

Based on the current evidence, bDMARDs and tsDMARDs should be preferably administered in combination with MTX. Several studies have established that a combination of bDMARDs with at least 10mg/week of MTX, increases the efficacy and retention rate of treatment^{64, 100, 118-128}.

Since the 2016 update, increasing evidence is also favoring the use of tsDMARD in combination with MTX. In the ORAL Strategy trial, tofacitinib monotherapy was not shown to be non-inferior to tofacitinib combined with MTX¹⁰³. A post-hoc analysis showed that the efficacy outcomes were similar for tofacitinib monotherapy and tofacitinib plus MTX in early RA (≤ 2 years of disease duration) but were higher with the combination therapy than with tofacitinib monotherapy in established RA (>2 years)¹²⁹. Nonetheless, real-world data from the US Corrona registry did not show significant differences in efficacy outcomes between tofacitinib monotherapy and tofacitinib combined with MTX¹³⁰. In the RA-BEGIN phase 3 trial, baricitinib in combination with MTX conveyed significantly less radiographic progression than baricitinib monotherapy in an MTX-naïve population, although similar clinical and functional outcomes were noted¹³¹. However, no trials have compared baricitinib monotherapy with baricitinib combined with MTX in an MTX-inadequate response population.

In patients who cannot use concomitant therapy with csDMARDs, tocilizumab remains the only bD-

MARD with demonstrated consistent evidence of efficacy in monotherapy for symptomatic control and inhibition of radiographic progression^{83, 130, 132-135}. However, in a recent analysis of the tocilizumab randomized trials, combination therapy with tocilizumab plus MTX proved to be more effective in preventing radiographic progression when compared to tocilizumab-monotherapy¹³⁶. Still, in this study, the effectiveness of tocilizumab-monotherapy seems to approximate the effectiveness of the tocilizumab plus MTX in early RA patients with more joint damage and/or a lower DAS28 at baseline, and in established RA patients with longer disease duration¹³⁶. Furthermore, a large observational study using data from the TOcilizumab Collaboration of European Registries in RA (TOCERRA) showed shorter drug retention under monotherapy, compared to combination therapy with csDMARDs, with an increasing difference over time after 1.5 years¹³⁷. However, more recent data using the same registry showed that the risk of tocilizumab discontinuation was similar between monotherapy and combination therapy with csDMARDs in patients who had inadequate response to one or more bDMARDs¹³⁸. Accordingly, in a multicentre cohort study using the Japanese ACTRA-RI registry, there was no difference in the duration of tocilizumab retention between monotherapy and combination therapy with MTX¹³⁹.

Although the results from ORAL Strategy and RA-BEGIN favored the combination therapy, they have also highlighted the potential efficacy of JAKis in monotherapy. Additionally, both tofacitinib and baricitinib as monotherapy have proven to be superior in efficacy compared to placebo¹⁴⁰⁻¹⁴² and to MTX alone¹⁴³⁻¹⁴⁵. Likewise, in the SELECT-EARLY trial, upadacitinib alone was superior to MTX in patients with predominantly early RA who were naïve for or had limited exposure to MTX¹⁴⁶.

If MTX is not tolerated or is contraindicated, IL-6R inhibitors and tsDMARDs should be considered preferential choices. TNFi approved in monotherapy can also be considered in case of patients with certain conditions: moderate hepatic impairment, high cardiovascular risk, high risk of blood clots and in women planning pregnancy (see recommendation 10).

Concerning bsDMARDs, the SPR position has been discussed in a separated article¹⁴⁷.

Of note, the cost-effectiveness of the drugs should also be taken into account in the treatment decision-making. The high prices of bDMARDs and tsDMARDs increases the direct costs of RA management and put pressure on the healthcare budgets. It is known that countries' socioeconomic status, affordability of bDMARDs and prescription and reimbursement rules influence the usage of these drugs¹⁴⁸. On the other

hand, the economic burden of RA includes not only direct costs (e.g. drug, inpatient and outpatient costs), but also indirect costs, such as those related to loss of productivity due to sick leave, reduced work performance and early retirement¹⁴⁹. Indeed, the use of effective DMARDs can decrease both direct and indirect costs¹⁵⁰⁻¹⁵³. Overall, while efficacy and safety data should primarily underpin treatment decisions, cost issues should also be considered.

RECOMMENDATION 7

Rituximab can be considered as a first-line biological treatment in case of patients with other conditions: hematologic neoplasms [B-cell-lymphomas, acute lymphoblastic leukaemia or monoclonal gammopathy of undetermined significance (MGUS)], suspected latent tuberculosis in patients with contraindication to chemoprophylaxis, demyelinating diseases or specific manifestations of RA. The evidence of rituximab use in patients with recent solid neoplasms does not allow to state any recommendation; thus, a decision should be made case by case.

Rituximab has been used in patients with RA. However, the largest experience comes from its use in the treatment of some haematologic neoplasms like B-cell-lymphomas and acute lymphoblastic leukaemia. Based on this, it seems reasonable that in patients with active RA and current or recent history of these cancers, for whom other biological treatments and tsDMARDs are contra-indicated, rituximab could be used. There is no evidence to support the recommendation of rituximab use in case of recently cured neoplasms¹⁵⁴. However, the absence of an increased risk of cancer in patients treated with rituximab supports the choice of some rheumatologists who prioritize rituximab in this setting^{2, 155}. This measure should be carefully decided, based on individual risk-benefit and involving the oncology team. Cases of tuberculosis have not been identified in patients receiving rituximab¹⁵⁶. Although rituximab therapy remains contra-indicated in active tuberculosis, its use can be considered in patients with suspected latent tuberculosis or living in endemic regions of tuberculosis who have contra-indication for chemoprophylaxis. bDMARDs are contra-indicated in patients with demyelinating diseases. Nevertheless, rituximab has been successfully used in patients with optic neuropathy and patients with other central nervous system demyelinating diseases, as multiple sclerosis, or with peripheral demyelinating neuropathies¹⁵⁷⁻¹⁶⁰. In patients suffering from both diseases (RA and demyelinating disease), rituximab could be considered.

RECOMMENDATION 8

Patients who failed a first bDMARD or tsDMARD should be treated with another bDMARD or tsDMARD. If the first bDMARD was a TNFi, the patient may receive a bDMARD with a different mode of action or a tsDMARD (swapping), or a second TNFi (cycling):

-A swapping strategy is recommended if the reason for discontinuation is a primary failure of a first TNFi or after two consecutive failures with TNFis;

-Following secondary failure or an adverse event to a first TNFi, cycling or swapping strategies are both acceptable.

The treatment goal of remission or low disease activity should be achieved after six months of therapy. However, the therapeutic response should be firstly assessed after three months on biological treatment or under a tsDMARD. It is expected to obtain at least a minimal clinical improvement (change in DAS28 >1.2 or change from high to moderate disease activity). In the absence of minimal clinical response at three months, it is unlikely that the treatment goal will be achieved even after one year of treatment¹⁶¹, hence the treatment strategy should be redefined. Non-improvement at three months, or failing to achieve remission, or at least low disease activity, at six months should be considered a treatment failure.

Because of their long-term data on efficacy and safety, TNFis have been usually the first choice of biological therapy. Notwithstanding, approximately 30-40% of patients discontinue TNFis due to primary failure, secondary loss of response or intolerance^{55, 162, 163}.

Management of TNFi failure can include switching to an alternative TNFi (cycling) or to another class of targeted agents with a different mode of action (swapping)¹⁶⁴.

All bDMARDs and tsDMARDs proved efficacious in case of TNFi failure and are approved for this indication.

The cycling strategy is well established and supported by some RCTs (the OPPOSITE trial¹⁶⁵, the GO-AFTER^{166, 167}, the REALISTIC¹⁶⁸ and the EXXELERATE¹⁶⁹ study) and by several observational studies based on national registries or multicentric cohorts, which have highlighted a good efficacy profile and drug retention rate in RA patients receiving a second TNFi, comparing to placebo¹⁷⁰⁻¹⁷⁹. A recent meta-analysis including six RCTs and eighteen observational studies indicated that in TNF-experienced RA patients, subsequent TNFi therapy and subsequent non-TNF biologic therapy have comparable efficacy¹⁸⁰. However, the overall performance of TNFi progressively decreases with the

increasing number of previously failed agents.

Regarding the choice of the second TNFi, a multicentric, retrospective study based on an Italian cohort (LORHEN registry) that included 195 RA patients who switched from a first TNFi to etanercept, adalimumab, or golimumab, found that second-line golimumab has an overall better 2-year drug survival¹⁸¹. On the other hand, reasons for discontinuation of a first TNFi might influence the efficacy of a second TNFi. In fact, some studies, including a randomized trial, suggest that primary non-responders to TNFi are less likely to respond to a second TNFi than secondary non-responders to a TNFi or patients that discontinued the first TNFi following an adverse event^{174, 175, 177, 182, 183}.

On the other hand, the use of abatacept, rituximab, IL-6R inhibitors (tocilizumab), or JAK inhibitors (tofacitinib, baricitinib, upadacitinib) as a second-line agents (swapping strategy) is also strongly supported by RCTs (ATTAIN^{184, 185}), REFLEX⁹¹, RADIATE¹⁸⁶, ORAL STEP¹⁸⁷, RA-BEACON^{188, 189}, SELECT-BEYOND¹⁹⁰ and by real-life experiences^{84, 92, 94, 97, 98, 191-204}.

The best strategy after failure of a first TNFi has been intensely discussed in the last few years, and evidence is still conflicting when comparing the use of a second TNFi (cycling strategy) to a drug with a different mechanism of action (swapping strategy). The 2016 Portuguese recommendations¹⁴ already pointed to the existence of data suggesting that patients with inadequate response to a TNFi who switched to a non-TNFi agent (tocilizumab, rituximab or abatacept) had significantly higher drug retention rates, compared to those that remain on TNFi treatment. Moreover, in the last few years, and due to the growing experience using these agents, new data on comparison of both strategies has emerged. A recent head-to-head, open-label RCT randomized 300 RA patients who failed a first TNFi to receive either a second TNFi or a non-TNFi biological agent (abatacept, rituximab, tocilizumab). The proportion of patients reaching a good or moderate EULAR response at week 24 (the primary endpoint) was higher in patients who received a non-TNFi biological agent, although the switching strategy was also often successful (69% VS 52%, OR, 2.06; 95%CI, 1.27-3.37; P = .004). There were no significant differences within the non-TNFi group¹⁹¹. Nevertheless, most data comparing the switching and swapping strategy comes from observational studies and national registries, with real-life observational data favoring the swapping strategy over the cycling strategy^{84, 92, 94, 97, 98, 192-204}). In Portugal, Santos-Faria *et al.* recently conducted a multicentric, non-interventional prospective study with 643 RA patients included in Reuma.pt registry who failed a first TNFi, showing higher drug retention rates (reflecting both effectiveness and safety) for rituximab and tocili-

zumab compared to a second TNFi, with similar persistence among tocilizumab and rituximab¹⁹⁹. Even though there is more data regarding the use of abatacept, rituximab, and tocilizumab, some recent studies also included tofacitinib in this sort of analysis^{196, 197}. Moreover, a 2016 meta-analysis including five RCTs that evaluated tofacitinib or bDMARDs against placebo after TNFi insufficient response demonstrated that tofacitinib 5 mg twice daily combined with MTX was found to have comparable ACR response and change from baseline in HAQ index with abatacept, golimumab, rituximab, and tocilizumab²⁰⁵. Concerning the choice between the non-TNFi drugs, there are conflicting data about which might be the best swapping option, not allowing for a specific recommendation, although the majority seem to favor rituximab or tocilizumab^{92, 94, 98, 193, 202, 206}.

With growing data on non-TNFi drug efficacy and safety, their use as first bDMARD is spreading. Hereupon, a new issue emerged on how to manage a non-TNFi failure. Some small exploratory studies^{200, 207, 208} and a small RCT²⁰⁹ showed that both TNFi and other non-TNFi are a suitable option after a non-TNFi failure, with higher retention rates in the swapping strategy²⁰⁹. To the best of our knowledge, studies on tsDMARDs failures are lacking. Due to the lack of good quality studies, no specific recommendation can be made regarding the best treatment strategy after failure of a first non-TNFi agent or JAKi as first-line targeted therapy, although increasing evidence suggests that changing the mechanism of action might lead to more efficacious results.

In summary all bDMARDs (TNFi and non-TNFi) and tsDMARDs have proved to be effective after the failure of a first TNFi. However, data from registries and observational studies appear to favor a change of the mechanism of action (for IL-6 inhibition, B cell depletion or T cell co-stimulation) as the best strategy for the treatment of these patients, with this being particularly true if the first TNFi is discontinued following inadequate response. JAK inhibition could also be considered but robust data comparing these agents with bDMARDs is missing. Due to lack of data, no specific recommendation could be made regarding the best treatment strategy after failure of a first non-TNFi agent or JAKi as first-line therapy.

RECOMMENDATION 9

In case of sustained remission, tapering bDMARDs or tsDMARDs can be considered, especially in patients with concomitant csDMARDs treatment. No specific recommendations about tapering regimens can be made at the moment.

Since 2011, several studies have demonstrated that bD-

MARDs can be tapered or even stopped without causing flares in a considerable percentage of patients²¹⁰⁻²¹⁶. In established RA, the available data suggest that many patients flare upon withdrawal of a TNFi, while those who tapered bDMARD more frequently maintain low disease activity and present less radiographic progression^{215, 217, 218}. In the PRESERVE trial, patients assigned to receive etanercept at a lower dose (25 mg/wk) continued to have low disease activity in the double-blind period whereas those who received placebo (maintenance of csDMARDs only) had a mean disease activity in the moderate range. The groups given etanercept (50mg/wk or 25mg/wk) kept similar patterns of response and maintained a better efficacy than the group given placebo²¹⁷. Similar findings were obtained in other studies^{218, 219}.

Contradictory results were observed in early arthritis. In the PRIZE trial, after attainment of sustained remission in early RA, dose reduction of etanercept, but not the withdrawal of the biologic, was accompanied by maintenance of response, with 63.5% of patients remaining in remission (DAS28 <2.6 at week 76 and 91 visits)²¹⁶. Likewise, in the open label extensions of OPTIMA²²⁰ and HIT HARD²¹¹ studies, patients under bDMARD and MTX who withdraw the biologic agent, maintained good clinical^{211, 220}, radiographic^{211, 220} and functional response²²⁰.

Even though most studies on dose reduction or withdrawal have been performed with TNFis, data on other bDMARDs (abatacept and tocilizumab) are emerging with similar overall results. However, the percentage of patients in remission at the end of the withdrawal studies has been small, ranging from 9 to 44%^{73, 128, 134, 221-223}. Only one observational cohort study²²⁴ evaluated dose reduction of tocilizumab, yielding at the end of the 24-week study, 55% of patients in low disease activity. In early arthritis, a more profound and persistent response increases the likelihood of maintaining a good outcome after withdrawal of a bDMARD, maintaining therapy with csDMARDs²²⁵. Gradual bDMARD dose reduction may be a better strategy than abrupt discontinuation^{216-219, 226}. In case of relapse, reintroduction of the bDMARD appears to allow the return to a favorable outcome^{221, 225, 227, 228}.

Among tsDMARDs, the evidence on dose reduction is even scarcer. The RA-BEYOND study randomized patients from four trials on baricitinib at 4 mg who had achieved stable CDAI ≤ 10 to either continue 4 mg or reduce the dose to 2 mg. While more patients who continued full dose maintained CDAI low disease activity compared with those who reduced the dose (93% vs 83%, $p < 0.001$ at three months; 87% vs 75%, $p < 0.001$, at six months; 80% vs 67%, $p < 0.01$ at 12 months for baricitinib 4 mg continuation vs dose reduction to

baricitinib 2 mg, respectively), a majority of patients maintained their good disease state despite dose reduction. Further, in patients being in CDAI \leq 2.8 at randomization, fewer patients worsen their disease activity state. Of those who flared after dose reduction, most (66.7%) regained their CDAI <10 state within 24 weeks after a dose increase to 4 mg. Thirteen of the 16 patients who did not regain their CDAI <10 state after 24 weeks were able to do so at a subsequent time point²²⁹.

Importantly, before bDMARDs or tsDMARDs tapering, glucocorticoids should be withdrawn².

RECOMMENDATION 10

In case of pregnancy, and always based on a shared decision between patient and physicians (rheumatologist and obstetrician), patients may be treated with most TNFi in its early stages. Certolizumab can be used throughout pregnancy. The use of TNFi is appropriate during breastfeeding.

tsDMARDs and some bDMARDs (rituximab, abatacept and tocilizumab) should be avoided in pregnant and breastfeeding women.

There is no indication to stop bDMARD in males who wish to become parents.

TNFis are the best-studied biologic agents during pregnancy and safety data on TNFis during pregnancy is reassuring. The benefits of TNFis in controlling disease and achieving remission seem at current knowledge to outweigh the theoretical risk of fetus exposition to the drug. The decision should be shared between the patient and physicians (rheumatologist and obstetrician), balancing risks and benefits. TNFis differ in structure: adalimumab, infliximab, and golimumab are whole monoclonal IgG1 antibodies, etanercept only contains a part of the Fc-region of IgG1 and certolizumab is a PEGylated fragment antigen-binding (Fab) and contains no Fc region^{230, 231}. Active transport of TNFis over the placenta into the fetal circulation is mediated through binding to the fetal Fc receptor and occurs as early as week 18 of gestation. Adalimumab and infliximab have a high affinity for the fetal Fc receptor; etanercept binds weakly to this receptor; certolizumab does not bind to this receptor at all since it does not contain an Fc-region. Hence, the level of TNFi that can be detected in the cord blood is associated with the type of TNFi^{230, 231}. In addition, placental transfer increases over time and therefore the timing of administration during pregnancy is associated with the level of TNFi that can be detected in the cord blood. The lowest levels of anti-TNF in the cord blood are observed for certolizumab and etanercept. Exposure to infliximab and adalimumab,

especially later in pregnancy, results in higher levels of the drug detectable in the umbilical cord blood compared to etanercept and certolizumab. Both infliximab and adalimumab can be detected in the infant serum up to one year for infliximab and up to 9 months for adalimumab^{231, 232}. The best timing to stop anti-TNF treatment so that no levels of TNFis in the umbilical cord can be detected is yet to be determined. So, in line with the EULAR recommendations, we advocate stopping infliximab and adalimumab treatment at 20 weeks of gestation and etanercept at 30-32 weeks of pregnancy; we also advise that the use of certolizumab throughout the whole pregnancy is safe^{230, 231}. Due to a lack of safety data, the use of golimumab is not advised during pregnancy^{230, 231}. When taking all data together, no increased risk of congenital malformations in infants exposed to TNFis was found, and most importantly, no specific pattern of malformations could be observed^{231, 233}. In addition, other authors showed, in a large study, no excess risk of serious infections after in utero exposure to a TNFi^{231, 234}. However, we can say that the use of biologics in pregnancy is still controversial because safety for the fetus and neonate has been proven only for TNFis. Moreover, long-term outcomes for exposed children have not been studied for any biologic. Thus, extended long-term studies are needed to clarify whether biologics may affect immune function in prenatally exposed children. Safety data on other biologic agents (tocilizumab, abatacept and rituximab) and tsDMARDs is insufficient and the use of these agents is not advised during pregnancy^{230, 231}. They are, therefore, best discontinued before a planned pregnancy, respecting the washout period between drug discontinuation and pregnancy, which vary according to the drug.

The JAK-STAT pathway has been shown to be involved in cell-cell adhesion and in cell polarity, which could condition the earlier stages of embryogenesis²³⁵. In rats, at a dose 73 times, but not 29 times, the therapeutic dose of 10mg twice daily, tofacitinib was teratogenic and caused fetal death²³⁶. Similarly in rabbits, at a dose 6.3 times, but not 1.5 times, the therapeutic dose of 10mg twice daily, teratogenic effects and post-implantation loss were verified²³⁶. Tofacitinib had no impact on male fertility or sperm quality or motility in animal studies²³⁶. In murine models, baricitinib, at doses higher than 20-times the human labelled dose, has shown to reduce fertility, to have a teratogenic effect, reduce bone growth and fetal weight in uterus and increase embryo death²³⁵. However, in humans, exposure to tofacitinib during conception and pregnancy in rheumatic diseases or ulcerative colitis seems not to be associated with increased risk to the fetus²³⁷⁻²³⁹. Moreover, a recent report of exposure to baricitinib during the first 17 weeks of pregnancy, outside the drug regis-

Table II. Recommendations for the use of biological therapies and tsDMARDs in rheumatoid arthritis

Domain	Recommendation	Agreement mean (SD)
General recommendation*	Rheumatologists are the specialists who should primarily care for RA patients. Treatment of RA patients with bDMARDs and tsDMARDs must be based on a shared decision between patient and rheumatologist.	9.9 (0.4)
	All RA patients receiving bDMARDs and tsDMARDs should be prospectively registered in the Reuma.pt.	9.0 (1.6)
Monitoring*	Monitoring RA patients under treatment with bDMARDs and tsDMARDs is mandatory. These patients should be evaluated at closely spaced intervals, no longer than 3-4 months, to assess disease activity and safety issues. Function, quality of life and damage should also be evaluated during follow-up.	9.2 (1.1)
Treatment target*	The treatment target is remission or, at least, low disease activity.	9.7 (0.7)
Treatment indication*	RA patients with inadequate response to MTX at an optimal dose and for an adequate period of time, or to at least one other csDMARD or in case of contraindication or intolerance to MTX, should be considered for bDMARDs or tsDMARDs therapy.	9.3 (1.3)
First-line treatment	If it is not possible to achieve the treatment target with an optimal csDMARD strategy or if there is contraindication/intolerance to it, a bDMARD or a tsDMARD should be considered, preferably combined with a csDMARD. In patients who cannot use csDMARDs, IL-6 inhibitors or tsDMARDs should be considered.	9.2 (1.0)
Specific comorbidities*	Rituximab can be considered as a first-line biological treatment in case of patients with other conditions: hematologic neoplasms [B-cell-lymphomas, acute lymphoblastic leukaemia or MGUS], suspected latent tuberculosis in patients with contraindication to chemoprophylaxis, demyelinating diseases or specific manifestations of RA. The evidence of rituximab use in patients with recent solid neoplasms does not allow to state any recommendation; thus, a decision should be made case by case.	9.2 (0.9)
Inadequate response	Patients who failed a first bDMARD or tsDMARD should be treated with another bDMARD or tsDMARD. If the first bDMARD was a TNFi, the patient may receive a bDMARD with a different mode of action or a tsDMARD (swapping), or a second TNFi (cycling): -A swapping strategy is recommended if the reason for discontinuation is a primary failure of a first TNFi or after two consecutive failures with TNFis; -Following secondary failure or an adverse event to a first TNFi, cycling or swapping strategies are both acceptable.	9.4 (0.7)
Sustained remission*	In case of sustained remission, tapering bDMARDs or tsDMARDs can be considered, especially in patients with concomitant csDMARDs treatment. No specific recommendations about tapering regimens can be made at the moment.	9.2 (1.1)
Pregnancy and breastfeeding	In case of pregnancy, and always based on a shared decision between patient and physicians (rheumatologist and obstetrician), patients may be treated with most TNFi in its early stages. Certolizumab can be used throughout pregnancy. The use of TNFi is appropriate during breastfeeding. tsDMARDs and some bDMARDs (rituximab, abatacept and tocilizumab) should be avoided in pregnant and breastfeeding women.	9.3 (1.0)
	There is no indication to stop bDMARD in males who wish to become parents.	9.4 (0.8)

Agreement was voted on a scale 1 to 10 (fully disagreement to fully agreement) by 102 Rheumatologists. *These recommendations remained mostly unchanged compared to 2016. bDMARDs, biologic disease-modifying anti-rheumatic Drugs. csDMARDs, conventional synthetic disease-modifying antirheumatic drugs. MGUS, monoclonal gammopathy undetermined significance. MTX, methotrexate. RA, Rheumatoid Arthritis. TNFi, Tumor Necrosis Factor inhibitor. tsDMARDs, targeted synthetic disease-modifying antirheumatic drugs.

tration program, has been published and no teratogenicity was found²³⁵.

There is only limited data available on the effect of stopping TNFi treatment on disease course in pregnant patients. Most literature suggests that stopping TNFis just before or during pregnancy may result in a flare during pregnancy or in the peri- and the postpartum

period. Contrary, other authors showed that in patients with inactive disease, discontinuing TNFis before the 20th week of gestation did not result in active disease later in pregnancy^{231, 240}.

Infants who have been exposed in the second or third trimester of pregnancy to a TNFi should not receive live-attenuated vaccines (like varicella, measles,

mumps, rubella, rotavirus, intranasal influenza and BCG) in their first six months of life^{230, 231}. Infants exposed to a TNFi before the 22nd week of gestation can get vaccinated, including with live vaccines, according to standard vaccine protocols^{230, 231}. Vaccination appears to be effective in infants previously exposed to TNFis in utero.

Breastfeeding during the use of TNFis (infliximab, adalimumab, etanercept, golimumab and certolizumab) is appropriate since minimal transfer of the TNFi into breast milk occurs^{230, 231}. tsDMARDs and bDMARDs with no data on breast feeding (rituximab, tocilizumab and abatacept) should be avoided during lactation²³⁰.

Birth outcomes in children fathered by men treated with biologics before conception have been studied for TNFis²⁴¹; for other biologics, data are anecdotal and of poor quality²⁴². Those studies did not show any negative impact regarding live births or congenital abnormalities^{243, 244}. In men planning to conceive, due to a lack of safety data, JAKis should be discontinued.

GENERAL SAFETY CONSIDERATIONS bDMARD and tsDMARD therapies are contra indicated in the following situations:

- 1) active infection (including opportunistic infections, active tuberculosis; human immunodeficiency virus, hepatitis C virus and hepatitis B virus infections)
- 2) Malignancy:
 - Current or recent history of cancer (≤ 5 years), except basal and squamous cell skin cancer after complete excision
 - No recommendations are possible at this moment regarding pre-malignant conditions
 - In some cases, Rituximab can be considered (see recommendation 7). The use of other non-TNFis agents can be considered in individual cases based on benefit/risk assessment.
- 3) Concurrent administration of live vaccines
- 4) Heart Failure (New York Heart Association Class III or IV), in case of rituximab and TNFi
- 5) Demyelinating disease, except rituximab that can be used in some situations

Tuberculosis screening before introduction of tsDMARDs and biological therapies

Evaluation for latent and active tuberculosis should be performed in all patients with joint inflammatory diseases before starting bDMARDs in accordance with the recommendations developed by SPR and the Portuguese Society of Pneumology²⁴⁵. By extrapolation and general consensus, the same assessment should be performed before starting treatment with a tsDMARD.

Criteria for temporary suspension/ postponement of introduction of biological therapies

This issue is detailed in the practical guide for prescribing biological therapies published by SPR²⁴⁶.

CONCLUSION

bDMARDs and, more recently, tsDMARDs reflect an advance in the approach of RA patients. Its use plays an important role in RA treatment, leading to better outcomes. These updated recommendations reflect the new evidence on efficacy and safety published since 2016. The use of bDMARDs and tsDMARDs should be monitored regularly, regarding clinical efficacy and safety. Remission or at least low disease activity should be the treatment target. Precautions related to adverse events and contra-indications should be considered when these drugs are used. New drugs are being developed [other JAKis and IL-6 antagonists and drugs with new mechanisms of action]; thus, these recommendations should be updated when new evidence becomes available.

REFERENCES

1. Branco JC, Rodrigues AM, Gouveia N, Eusebio M, Ramiro S, Machado PM, et al. Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt- a national health survey. *RMD Open*. 2016;2(1):e000166.
2. Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*. 2020;79(6):685-99.
3. van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. *Ann Rheum Dis*. 2014;73(5):861-70.
4. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis*. 2010;69(4):631-7.
5. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*. 2016;75(1):3-15.
6. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26.
7. European, Medicines, Agency. Baricitinib: Olumiant® (baricitinib): summary of product characteristics <https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant>. [
8. European, Medicines, Agency. Tofacitinib: Xeljanz® (tofacitinib): summary of product characteristics <https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz>. [
9. European, Medicines, Agency. Upadacitinib: Rinvoq® (upadacitinib): summary of product characteristics <https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq>. [

- ema.europa.eu/en/medicines/human/EPAR/rinvoq. [European Medicines Agency. Filgotinib: Jyseleca® (filgotinib): summary of product characteristics. <https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca>]
10. Consensos do Grupo de Estudos de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia para utilização de DMARD biológicos. *Acta Reumatol Port* 2003;187-9.
 11. Fonseca JE, Canhao H, Reis P, Santos MJ, Branco J, Quintal A, et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update. *Acta Reumatol Port*. 2010;35(1):95-8.
 12. Fonseca JE, Bernardes M, Canhao H, Santos MJ, Quintal A, Malcata A, et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 update. *Acta Reumatol Port*. 2011;36(4):385-8.
 13. Duarte C, Sousa-Neves J, Agueda A, Ribeiro P, Daniel A, Eugenio G, et al. Portuguese Recommendations for the use of biological therapies in patients with rheumatoid arthritis- 2016 update. *Acta Reumatol Port*. 2017;42(2)(Apr-Jun):112-26.
 14. Guidelines for the use of biologic therapies in rheumatoid arthritis—December 2006 update. *Acta Reumatol Port* 2007;32(1):37-41.
 15. Portuguese guidelines for the use of biological agents in rheumatoid arthritis - December 2007 update. . *Acta Reumatol Port* 2007;32(4):363-6.
 16. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. *Arthritis Rheum*. 1995;38(1):38-43.
 17. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). *Clin Exp Rheumatol*. 2005;23(5 Suppl 39):S14-8.
 18. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol*. 2000;27(1):261-3.
 19. Canhao H, Faustino A, Martins F, Fonseca JE, Rheumatic Diseases Portuguese Register Board Coordination PSoR. Reuma.pt - the rheumatic diseases portuguese register. *Acta Reumatol Port*. 2011;36(1):45-56.
 20. Ward MM, Leigh JP, Fries JF. Progression of functional disability in patients with rheumatoid arthritis. Associations with rheumatology subspecialty care. *Arch Intern Med*. 1993;153(19):2229-37.
 21. Rat AC, Henegariu V, Boissier MC. Do primary care physicians have a place in the management of rheumatoid arthritis? *Joint Bone Spine*. 2004;71(3):190-7.
 22. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. *Arthritis Rheum*. 2005;53(2):241-8.
 23. Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards. *Ann Intern Med*. 1997;127(1):52-60.
 24. Widdifield J, Bernatsky S, Paterson JM, Thorne JC, Cividino A, Pope J, et al. Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. *Arthritis Care Res (Hoboken)*. 2011;63(1):53-7.
 25. Bonafede MM, Fox KM, Johnson BH, Watson C, Gandra SR. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. *Clin Ther*. 2012;34(2):457-67.
 26. D. Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. . *J Rheumatol*. 1997;24(12):2283-90.
 27. Voshaar MJ, Nota I, van de Laar MA, van den Bemt BJ. Patient-centred care in established rheumatoid arthritis. *Best Pract Res Clin Rheumatol*. 2015;29(4-5):643-63.
 28. E. Dilla T, Rentero ML, Comellas M, Lizan L, Sacristan JA. Patients' Preferences for Rheumatoid Arthritis Treatments and their Participation in the Treatment Decision-Making Process. A Systematic Review of the Literature. *Value Health*. 2015;18(7):A652.
 29. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. *Rheum Dis Clin North Am*. 2009;35(4):745-57, vii-viii.
 30. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology (Oxford)*. 2003;42(2):244-57.
 31. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. *Arthritis Res Ther*. 2005;7(4):R796-806.
 32. André Santos R, Reis P, Rebelo L, Costa Dias F, Miranda Rosa C, Viana de Queiroz M. "Health assessment questionnaire" adaptação para língua portuguesa e estudo da sua aplicabilidade. . *Acta Reumatol Port*. 1996;21(76):15-20.
 33. Ferreira PL. [Development of the Portuguese version of MOS SF-36. Part I. Cultural and linguistic adaptation]. *Acta Med Port*. 2000;13(1-2):55-66.
 34. Ferreira PL. [Development of the Portuguese version of MOS SF-36. Part II --Validation tests]. *Acta Med Port*. 2000;13(3):119-27.
 35. Ferreira LN, Ferreira PL, Pereira LN, Oppe M. The valuation of the EQ-5D in Portugal. *Qual Life Res*. 2014;23(2):413-23.
 36. Ferreira LN, Ferreira PL, Pereira LN, Oppe M. EQ-5D Portuguese population norms. *Qual Life Res*. 2014;23(2):425-30.
 37. Ferreira PL, Ferreira LN, Pereira LN. Contribution for the validation of the Portuguese version of EQ-5D. *Acta Med Port*. 2013;26(6):664-75.
 38. Combe B, Logeart I, Belkacemi MC, Dadoun S, Schaeffer T, Daures JP, et al. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. *Ann Rheum Dis*. 2015;74(4):724-9.
 39. Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. *Ann Rheum Dis*. 2015;74(2):415-21.
 40. Gaujoux-Viala C, Mouterde G, Baillet A, Claudepierre P, Fautrel B, Le Loet X, et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. *Joint Bone Spine*. 2012;79(2):149-55.
 41. Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, et al. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? *Ann Rheum Dis*. 2015;74(6):1132-7.
 42. Martins FM, da Silva JA, Santos MJ, Vieira-Sousa E, Duarte C, Santos H, et al. DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. *Rheumatology (Ox-*

- ford). 2015;54(2):286-91.
44. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Arthritis Rheum.* 2011;63(3):573-86.
 45. Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. *Ann Rheum Dis.* 2012;71(5):681-6.
 46. Contreras-Yanez I, Rull-Gabayet M, Pascual-Ramos V. Early disease activity suppression and younger age predict excellent outcome of recent-onset rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs. *Clin Exp Rheumatol.* 2012;30(3):402-8.
 47. Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. *Ann Rheum Dis.* 2012;71(10):1702-5.
 48. Navarro-Compan V, Gherghe AM, Smolen JS, Aletaha D, Landewe R, van der Heijde D. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. *Rheumatology (Oxford).* 2015;54(6):994-1007.
 49. Ferreira RJO, Santos E, Gossec L, da Silva JAP. The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this? *Semin Arthritis Rheum.* 2020;50(4):583-5.
 50. Santos E, Duarte C, Ferreira RJO, Pinto AM, Moreira A, Vaz C, et al. Portuguese multidisciplinary recommendations for non-pharmacological and non-surgical interventions in patients with rheumatoid arthritis. *Acta Reumatol Port.* 2021;46(1):40-54.
 51. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. *Ann Rheum Dis.* 2009;68(7):1094-9.
 52. Poor G, Strand V, Leflunomide Multinational Study G. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. *Rheumatology (Oxford).* 2004;43(6):744-9.
 53. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum.* 2004;50(11):3432-43.
 54. Smolen JS, Emery P. Infliximab: 12 years of experience. *Arthritis Res Ther.* 2011;13 Suppl 1:S2.
 55. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med.* 2000;343(22):1594-602.
 56. Pavelka K, Jarosova K, Suchy D, Senolt L, Chroust K, Dusek L, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. *Ann Rheum Dis.* 2009;68(8):1285-9.
 57. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. *J Rheumatol.* 2006;33(1):37-44.
 58. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet.* 1999;354(9194):1932-9.
 59. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. *Lancet.* 2009;374(9688):459-66.
 60. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. *Lancet.* 2012;379(9827):1712-20.
 61. Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B, et al. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. *J Rheumatol.* 2013;40(9):1487-97.
 62. Furst DE, Kavanaugh A, Florentinus S, Kupper H, Karunarathne M, Birbara CA. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. *Rheumatology (Oxford).* 2015;54(12):2188-97.
 63. Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. *J Rheumatol.* 2005;32(7):1232-42.
 64. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum.* 2006;54(1):26-37.
 65. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. *Arthritis Rheum.* 2009;60(8):2272-83.
 66. Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. *Ann Rheum Dis.* 2016;75(1):75-83.
 67. Keystone EC, Breedveld FC, van der Heijde D, Landewe R, Florentinus S, Arulmani U, et al. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. *J Rheumatol.* 2014;41(1):5-14.
 68. Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, et al. Efficacy and safety of golimumab as add-on therapy

- to disease-modifying antirheumatic drugs: results of the GO-MORE study. *Ann Rheum Dis.* 2014;73(8):1477-86.
69. Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. *J Rheumatol.* 2012;39(6):1185-91.
 70. Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. *J Rheumatol.* 2013;40(7):1097-103.
 71. Keystone E, Landewe R, van Vollenhoven R, Combe B, Strand V, Mease P, et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. *Ann Rheum Dis.* 2014;73(12):2094-100.
 72. Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, et al. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. *Arthritis Res Ther.* 2015;17:245.
 73. Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. *Ann Rheum Dis.* 2015;74(5):843-50.
 74. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. *Ann Rheum Dis.* 2014;73(1):86-94.
 75. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. *Arthritis Rheum.* 2013;65(1):28-38.
 76. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum.* 2008;58(10):2968-80.
 77. Bay-Jensen AC, Platt A, Byrjalsen I, Vergnoud P, Christiansen C, Karsdal MA. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. *Semin Arthritis Rheum.* 2014;43(4):470-8.
 78. Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, et al. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. *Mod Rheumatol.* 2014;24(3):399-404.
 79. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. *Ann Rheum Dis.* 2012;71(2):198-205.
 80. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database Syst Rev.* 2009(4):CD007848.
 81. Gallego-Galisteo M, Villa-Rubio A, Alegre-del Rey E, Marquez-Fernandez E, Ramos-Baez JJ. Indirect comparison of biological treatments in refractory rheumatoid arthritis. *J Clin Pharm Ther.* 2012;37(3):301-7.
 82. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. *PLoS One.* 2012;7(1):e30275.
 83. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet.* 2013;381(9877):1541-50.
 84. Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Turesson C, Askling J, et al. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. *Rheumatology (Oxford).* 2019.
 85. Romao VC, Santos MJ, Polido-Pereira J, Duarte C, Nero P, Miguel C, et al. Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. *Biomed Res Int.* 2015;2015:279890.
 86. De Cock D, Verschueren P. Primus inter pares: the choice of biologic drugs in rheumatoid arthritis. *Rheumatology (Oxford).* 2019;58(8):1325-6.
 87. Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Giulio Favalli E, et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. *Semin Arthritis Rheum.* 2016;45(5):519-32.
 88. Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J, et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. *Rheumatology (Oxford).* 2021;60(2):820-8.
 89. Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. *Ann Rheum Dis.* 2010;69(6):1158-61.
 90. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. *Arthritis Rheum.* 2008;59(6):785-93.
 91. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis Rheum.* 2006;54(9):2793-806.
 92. Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. *Ann Rheum Dis.* 2015;74(6):979-84.
 93. Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. *J Rheumatol.* 2012;39(12):2238-46.
 94. Gomez-Reino JJ, Maneiro JR, Ruiz J, Rosello R, Sanmarti R, Romero AB, et al. Comparative effectiveness of switching to

- alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. *Ann Rheum Dis.* 2012;71(11):1861-4.
95. Narvaez J, Diaz-Torne C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, et al. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. *Clin Exp Rheumatol.* 2011;29(6):991-7.
 96. Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP, Investigators R. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial. *J Rheumatol.* 2011;38(12):2548-56.
 97. Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, et al. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. *J Rheumatol.* 2015;42(7):1090-8.
 98. Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. *Arthritis Care Res (Hoboken).* 2012;64(8):1108-15.
 99. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. *Ann Rheum Dis.* 2011;70(9):1575-80.
 100. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med.* 2004;350(25):2572-81.
 101. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. *Ann Rheum Dis.* 2011;70(1):39-46.
 102. Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. *Arthritis Care Res (Hoboken).* 2011;63(5):711-20.
 103. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet.* 2017;390(10093):457-68.
 104. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. *N Engl J Med.* 2017;376(7):652-62.
 105. Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. *Arthritis Rheumatol.* 2019;71(11):1788-800.
 106. Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. *Ann Rheum Dis.* 2019;78(11):1454-62.
 107. Ferro F, Elefante E, Luciano N, Talarico R, Todoerti M. One year in review 2017: novelties in the treatment of rheumatoid arthritis. *Clin Exp Rheumatol.* 2017;35(5):721-34.
 108. Silvagni E, Di Battista M, Bonifacio AF, Zucchi D, Governato G, Scire CA. One year in review 2019: novelties in the treatment of rheumatoid arthritis. *Clin Exp Rheumatol.* 2019;37(4):519-34.
 109. Silvagni E, Giollo A, Sakellariou G, Ughi N, D'Amico ME, Scire CA, et al. One year in review 2020: novelties in the treatment of rheumatoid arthritis. *Clin Exp Rheumatol.* 2020;38(2):181-94.
 110. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. *Ann Rheum Dis.* 2017;76(7):1253-62.
 111. Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, et al. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. *J Rheumatol.* 2019;46(1):7-18.
 112. Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. *Ann Rheum Dis.* 2016;75(5):831-41.
 113. Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. *Semin Arthritis Rheum.* 2017;47(2):149-56.
 114. Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, et al. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. *Mod Rheumatol.* 2020;30(1):36-43.
 115. Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. *Arthritis Rheumatol.* 2017;69(10):1960-8.
 116. Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. *Ann Rheum Dis.* 2019;78(8):1048-54.
 117. Pfizer. Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA) - ORAL Surveillance Study (A3921133; NCT02092467) <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing> [
 118. Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S, et al. Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. *Adv Ther.* 2018;35(10):1535-63.
 119. Favalli EG, Pregnotato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, et al. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. *Arthritis Care Res (Hoboken).* 2016;68(4):432-9.
 120. Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised

- CONCERTO trial. *Ann Rheum Dis.* 2015;74(6):1037-44.
121. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. *Ann Rheum Dis.* 2012;71(11):1914-5.
 122. Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics R. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum.* 2006;54(6):1786-94.
 123. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. *J Rheumatol.* 2011;38(8):1585-92.
 124. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet.* 2004;363(9410):675-81.
 125. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Ann Rheum Dis.* 2009;68(6):789-96.
 126. Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). *Ann Rheum Dis.* 2016;75(11):1917-23.
 127. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. *Ann Rheum Dis.* 2016;75(6):1081-91.
 128. Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barre E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. *Ann Rheum Dis.* 2015;74(1):19-26.
 129. Takeuchi T, Tanaka Y, Sugiyama N, Iikuni N, Soma K, Shi H. Efficacy of tofacitinib monotherapy, tofacitinib with methotrexate and adalimumab with methotrexate in patients with early (≤ 2 years) vs established (>2 years) rheumatoid arthritis: a pos hoc analysis of data from Oral Strategy. *Ann Rheum Dis.* 2019;78:A373.
 130. Reed GW, Gerber RA, Shan Y, Takiya L, Dandreo KJ, Gruben D, et al. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis. *Rheumatol Ther.* 2019.
 131. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. *Arthritis Rheumatol.* 2017;69(3):506-17.
 132. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. *Mod Rheumatol.* 2009;19(1):12-9.
 133. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann Rheum Dis.* 2007;66(9):1162-7.
 134. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). *Ann Rheum Dis.* 2013;72(1):43-50.
 135. Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. *Ann Rheum Dis.* 2014;73(5):803-9.
 136. Verhoeven MMA, Tekstra J, Jacobs JWG, Bijlsma JWJ, van Laar JM, Petho-Schramm A, et al. Is tocilizumab monotherapy as effective in preventing radiographic progression in rheumatoid arthritis as its combination with methotrexate? *Arthritis Care Res (Hoboken).* 2020.
 137. Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomsic M, et al. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. *Ann Rheum Dis.* 2016;75(7):1336-42.
 138. Lauper K, Nordstrom DC, Pavelka K, Hernandez MV, Kvien TK, Kristianslund EK, et al. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. *Ann Rheum Dis.* 2018;77(9):1276-82.
 139. Mori S, Yoshitama T, Abe Y, Hidaka T, Hirakata N, Aoyagi K, et al. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study. *Rheumatology (Oxford).* 2019;58(7):1274-84.
 140. Kaufmann J, Feist E, Roske AE, Schmidt WA. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. *Clin Rheumatol.* 2013;32(9):1347-55.
 141. Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyozumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. *Mod Rheumatol.* 2015;25(4):514-21.
 142. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med.* 2012;367(6):495-507.
 143. Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. *Ann Rheum Dis.* 2017;76(1):88-95.

144. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. *N Engl J Med*. 2014;370(25):2377-86.
145. Strand V, Lee EB, Fleischmann R, Alten RE, Koncz T, Zwillich SH, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. *RMD Open*. 2016;2(2):e000308.
146. van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S, et al. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. *Arthritis Rheumatol*. 2020;72(10):1607-20.
147. Fonseca JE, Goncalves J, Araujo F, Cordeiro I, Teixeira F, Canhao H, et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars. *Acta Reumatol Port*. 2014;39(1):60-71.
148. Bergstra SA, Branco JC, Vega-Morales D, Salomon-Escoto K, Govind N, Allaart CF, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. *Ann Rheum Dis*. 2018;77(10):1413-20.
149. Hsieh PH, Wu O, Geue C, McIntosh E, McInnes IB, Siebert S. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. *Ann Rheum Dis*. 2020;79(6):771-7.
150. Batko B, Rolska-Wojcik P, Wladysiuk M. Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment-A Systematic Literature Review. *Int J Environ Res Public Health*. 2019;16(16).
151. ter Wee MM, Lems WF, Usan H, Gulpen A, Boonen A. The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. *Ann Rheum Dis*. 2012;71(2):161-71.
152. Matsumoto T, Nishino J, Izawa N, Naito M, Hirose J, Tanaka S, et al. Trends in Treatment, Outcomes, and Incidence of Orthopedic Surgery in Patients with Rheumatoid Arthritis: An Observational Cohort Study Using the Japanese National Database of Rheumatic Diseases. *J Rheumatol*. 2017;44(11):1575-82.
153. Nystad TW, Fenstad AM, Furnes O, Havelin LI, Skredderstuoen AK, Fevang BT. Reduction in orthopaedic surgery in patients with rheumatoid arthritis: a Norwegian register-based study. *Scand J Rheumatol*. 2016;45(1):1-7.
154. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2011;70(6):909-20.
155. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2016;68(1):1-25.
156. van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. *J Rheumatol*. 2015;42(10):1761-6.
157. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. *PLoS One*. 2013;8(7):e66308.
158. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. *JAMA Neurol*. 2013;70(9):1110-7.
159. Parfenov V, Du Pasquier R, Schlupe M. Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report. *Neurologist*. 2015;19(6):155-7.
160. Zephir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. *J Neurol*. 2015;262(10):2329-35.
161. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. *Arthritis Rheum*. 2007;56(10):3226-35.
162. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum*. 2004;50(5):1400-11.
163. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med*. 1999;340(4):253-9.
164. Smolen JS, Weinblatt ME. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? *Ann Rheum Dis*. 2008;67(11):1497-8.
165. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. *Ann Rheum Dis*. 2007;66(7):893-9.
166. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. *Lancet*. 2009;374(9685):210-21.
167. Smolen JS, Kay J, Doyle M, Landewe R, Matteson EL, Gaylis N, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. *Arthritis Res Ther*. 2015;17:14.
168. Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, et al. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. *Arthritis Res Ther*. 2015;17:325.
169. Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. *Lancet*. 2016;388(10061):2763-74.
170. Gomez-Reino JJ, Carmona L, Group B. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. *Arthritis Res Ther*. 2006;8(1):R29.
171. Caporali R, Sarzi-Puttini P, Atzeni F, Gorla R, Filippini M, Marchesoni A, et al. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. *Autoimmun Rev*. 2010;9(6):465-9.
172. Manara M, Caporali R, Favalli EG, Grosso V, Atzeni F, Sarzi-Puttini P, et al. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spon-

- dylitis: data from the LORHEN registry. *Clin Exp Rheumatol*. 2017;35(5):804-9.
173. Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. *Ann Rheum Dis*. 2007;66(2):249-52.
 174. Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). *Clin Rheumatol*. 2011;30(11):1447-54.
 175. Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, group A. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. *Ann Rheum Dis*. 2015;74(5):890-6.
 176. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. *Rheumatology (Oxford)*. 2007;46(7):1191-9.
 177. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics R. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. *Arthritis Rheum*. 2007;56(1):13-20.
 178. Codullo V, Iannone F, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, et al. Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. *Clin Exp Rheumatol*. 2017;35(4):660-5.
 179. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. *Ann Rheum Dis*. 2012;71(7):1134-42.
 180. Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A. Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. *Clin Ther*. 2017;39(8):1680-94 e2.
 181. Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, et al. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. *Int J Rheum Dis*. 2018;21(2):422-30.
 182. Remy A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. *Clin Exp Rheumatol*. 2011;29(1):96-103.
 183. Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. *Ann Rheum Dis*. 2014;73(12):2174-7.
 184. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med*. 2005;353(11):1114-23.
 185. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. *Ann Rheum Dis*. 2008;67(4):547-54.
 186. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis*. 2008;67(11):1516-23.
 187. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *Lancet*. 2013;381(9865):451-60.
 188. Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, et al. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. *Rheumatology (Oxford)*. 2018;57(5):900-8.
 189. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. *N Engl J Med*. 2016;374(13):1243-52.
 190. Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. *Lancet*. 2018;391(10139):2513-24.
 191. Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, et al. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. *JAMA*. 2016;316(11):1172-80.
 192. Favalli EG, Biggoggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. *Rheumatology (Oxford)*. 2014;53(9):1664-8.
 193. Chatzidionysiou K, van Vollenhoven RF. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. *Scand J Rheumatol*. 2013;42(3):190-5.
 194. Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. *Arthritis Rheum*. 2007;56(5):1417-23.
 195. Backhaus M, Kaufmann J, Richter C, Wassenberg S, Roske AE, Hellmann P, et al. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. *Clin Rheumatol*. 2015;34(4):673-81.
 196. Bonafede MM, Curtis JR, McMorro D, Mahajan P, Chen CI. Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. *Clinicoecon Outcomes Res*. 2016;8:707-15.
 197. Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, et al. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy. *Adv*

- Ther. 2017;34(8):1936-52.
198. Wilke T, Mueller S, Lee SC, Majer I, Heisen M. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. *BMC Musculoskelet Disord.* 2017;18(1):332.
 199. Santos-Faria D, Tavares-Costa J, Eusebio M, Leite Silva J, Ramos Rodrigues J, Sousa-Neves J, et al. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor. *Acta Reumatol Port.* 2019;44(2):103-13.
 200. Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFalpha blocker failure. *Biologics.* 2012;6:191-9.
 201. Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. *BMJ.* 2019;364:l67.
 202. Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, et al. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corona registry. *Arthritis Res Ther.* 2015;17:256.
 203. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? *Ann Rheum Dis.* 2010;69(2):387-93.
 204. Bessette L, Brown J, Coupal L, Haraoui B, Massicotte F, Pelletier J-P. Six Years Tocilizumab Use in Patients with Rheumatoid Arthritis with One Previous anti-TNF Agent Exposure: Comparison with Adalimumab and Etanercept from The Provincial Electronic Database and Registry Rhumadata®. *Ann Rheum Dis.* 2016;75:190.
 205. Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. *Clin Ther.* 2016;38(12):2628-41 e5.
 206. Lee YH, Bae SC. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. *Int J Rheum Dis.* 2016;19(11):1103-11.
 207. Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, et al. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study. *Int J Rheum Dis.* 2016;19(11):1093-102.
 208. Akiyama M, Kaneko Y, Kondo H, Takeuchi T. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. *Clin Rheumatol.* 2016;35(11):2829-34.
 209. Matsuno H, Katayama K. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab. *Mod Rheumatol.* 2017;27(2):246-51.
 210. van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. *Cochrane Database Syst Rev.* 2014(9):CD010455.
 211. Detert J, Bastian H, Listing J, Weiss A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. *Ann Rheum Dis.* 2013;72(6):844-50.
 212. Harigai M, Takeuchi T, Tanaka Y, Matsubara T, Yamanaka H, Miyasaka N. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. *Mod Rheumatol.* 2012;22(6):814-22.
 213. Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. *Ann Rheum Dis.* 2015;74(2):389-95.
 214. Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Hiramatsu K, et al. Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study. *RMD Open.* 2016;2(1):e000189.
 215. Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). *Ann Rheum Dis.* 2014;73(1):75-85.
 216. Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. *N Engl J Med.* 2014;371(19):1781-92.
 217. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. *Lancet.* 2013;381(9870):918-29.
 218. van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Klackenberga A. Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-armed, double-blind clinical trial. *Arthritis and Rheumatism.* 2012;64(12):4171.
 219. Botsios C, Furlan A, Ostuni P, Sfriso P, Todesco S, Punzi L. Effects of low-dose etanercept in maintaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis. *Annals of the rheumatic diseases.* *Ann Rheum Dis.* 2007;66:54.
 220. Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. *Lancet.* 2014;383(9914):321-32.
 221. Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, et al. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. *Rheumatology (Oxford).* 2015;54(4):683-91.
 222. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T,

- Iwahashi M, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. *Mod Rheumatol*. 2014;24(1):17-25.
223. Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, Morales-Torres J, Sanchez-Ortiz A, Sandoval-Castro C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. *J Rheumatol*. 2013;40(7):1069-73.
224. van Herwaarden N, Herfkens-Hol S, van der Maas A, van den Bemt BJ, van Vollenhoven RF, Bijlsma JW, et al. Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity. *Clin Exp Rheumatol*. 2014;32(3):390-4.
225. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. *Ann Rheum Dis*. 2010;69(7):1286-91.
226. Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid Arthritis Study). *Ann Rheum Dis*. 2016;75(1):59-67.
227. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, et al. Effect of discontinuing TNF α antagonist therapy in patients with remission of rheumatoid arthritis. *Joint Bone Spine*. 2009;76(4):350-5.
228. Allaart CF, Lems WF, Huizinga TW. The BeSt way of withdrawing biologic agents. *Clin Exp Rheumatol*. 2013;31(4 Suppl 78):S14-8.
229. Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. *Ann Rheum Dis*. 2019;78(2):171-8.
230. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. *Ann Rheum Dis*. 2016;75(5):795-810.
231. Smeele HTW, Dolhain R. Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis. *Semin Arthritis Rheum*. 2019;49(3S):S32-S5.
232. Julsgaard M, Christensen LA, Gibson PR, Geary RB, Fallingborg J, Hvas CL, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. *Gastroenterology*. 2016;151(1):110-9.
233. Chaudrey KH, Kane SV. Safety of Immunomodulators and Anti-TNF Therapy in Pregnancy. *Curr Treat Options Gastroenterol*. 2015;13(1):77-89.
234. Vinet E, De Moura C, Pineau CA, Abrahamowicz M, Curtis JR, Bernatsky S. Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study. *Arthritis Rheumatol*. 2018;70(10):1565-71.
235. Costanzo G, Firinu D, Losa F, Deidda M, Barca MP, Del Giacco S. Baricitinib exposure during pregnancy in rheumatoid arthritis. *Ther Adv Musculoskelet Dis*. 2020;12:1759720X19899296.
236. Agrawal M, Kim ES, Colombel JF. JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. *J Crohns Colitis*. 2020;14(Supplement_2):S755-S60.
237. Gerosa M, Argolini LM, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. *Expert Rev Clin Pharmacol*. 2018;11(10):987-98.
238. Mahadevan U, Dubinsky MC, Su C, Lawendy N, Jones TV, Marren A, et al. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. *Inflamm Bowel Dis*. 2018;24(12):2494-500.
239. Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, et al. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. *Drug Saf*. 2016;39(8):755-62.
240. Forger F, Bandoli G, Luo Y, Robinson L, Johnson DL, Chambers CD. No Association of Discontinuing Tumor Necrosis Factor Inhibitors Before Gestational Week Twenty in Well-Controlled Rheumatoid Arthritis and Juvenile Idiopathic Arthritis With a Disease Worsening in Late Pregnancy. *Arthritis Rheumatol*. 2019;71(6):901-7.
241. Larsen MD, Friedman S, Magnussen B, Norgard BM. Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-alpha Agents Before Conception. *Am J Gastroenterol*. 2016;111(11):1608-13.
242. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. *Rheumatology (Oxford)*. 2016;55(9):1693-7.
243. Viktil KK, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy-a population-based cohort study. *Pharmacoepidemiol Drug Saf*. 2009;18(8):737-42.
244. Paschou S, Voulgari PV, Vrabie IG, Saougou IG, Drosos AA. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. *J Rheumatol*. 2009;36(2):351-4.
245. Duarte R, Campainha S, Cotter J, Rosa B, Varela P, Correia A, et al. Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy. *Acta Reumatol Port*. 2012;37(3):253-9.
246. Mourao AF, Fonseca JE, Canhao H, Santos MJ, Bernardo A, Cordeiro A, et al. [Practical guide for the use of biological agents in rheumatoid arthritis - December 2011 update]. *Acta Reumatol Port*. 2011;36(4):389-95.